UNSPSC 51434951: Hydroflumethiazide/reserpine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434951 Hydroflumethiazide/reserpine is a Commodity code that does not match the actual work being solicited under it in recent state and local procurement activity. The City of Tampa's Purchasing Department posted an IFB in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, which included Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials — none of which are hydroflumethiazide or reserpine combination medications. The scope reflects emergency medical services procurement rather than the antihypertensive drug formulation the code nominally describes. State and local buyers have tagged this opportunity under the code, but the actual commodities being purchased diverge materially from the code's intended taxonomy category.

The City of Tampa's April 2026 solicitation is the only recent state and local opportunity visible under this code. The estimated contract value is $40,000, with a one-year term and two optional one-year renewals, plus unilateral extension rights for up to three additional 30-day periods at the same rates. The procurement included a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount capped at $10,000, and required vendors to submit Safety Data Sheets compliant with OSHA Hazard Communication Standards and accessibility documentation to WCAG 2.2 Level AA and Section 508 standards. The bid was due April 8, 2026, with award to the lowest responsive, responsible bidder within 120 days of opening. No additional state or local procurement activity under this code appears in the recent opportunity record.